Mckesson Corp 8-K, filed Feb 4, 2026
Mckesson Corp (MCK)
8-K
2026-02-04
For: 2026-02-04
View Original
Added on
April 02, 2026
About this 8-K
Mckesson Corp filed this 8-K on February 4, 2026.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 4, 2026
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of Principal Executive Offices, and Zip Code)
(972 ) 446-4800
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 4, 2026, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on December 31, 2025 which are attached hereto as Exhibit 99.1.
The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 4, 2026
| McKesson Corporation | ||||||||
| By: | /s/ Britt J. Vitalone | |||||||
| Britt J. Vitalone | ||||||||
| Executive Vice President and | ||||||||
| Chief Financial Officer | ||||||||
Exhibit 99.1
McKESSON CORPORATION REPORTS FISCAL 2026 THIRD QUARTER RESULTS
AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE
IRVING, Texas, February 4, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the third quarter ended December 31, 2025.
Third Quarter Highlights:
•Quarterly consolidated revenues of $106.2 billion increased 11%.
•Earnings per diluted share of $9.59 increased $2.64.
•Adjusted Earnings per Diluted Share of $9.34 increased 16%.
•Generated $1.2 billion of cash flow from operations and $1.1 billion of Free Cash Flow.
•McKesson closed the transaction to sell its Norwegian retail and distribution businesses to NorgesGruppen on January 30, 2026.
Fiscal 2026 Full Year Outlook:
•Raised and narrowed Adjusted Earnings per Diluted Share guidance range to $38.80 to $39.20, from the previous range of $38.35 to $38.85.
•Fiscal 2026 Adjusted Earnings per Diluted Share guidance range indicates 17% to 19% growth compared to the prior year.
•The Company does not forecast GAAP earnings per diluted share1.
"McKesson delivered another strong quarter, extending the momentum we've built across the enterprise and demonstrating the impact of our disciplined execution," said Brian Tyler, chief executive officer. "Our results highlight the strength of our core distribution businesses and the meaningful progress we are making against our strategic priorities."
"Our oncology and multispecialty platforms, together with our expanding suite of biopharma services programs, continue to create differentiated value and deepen the impact for our customers, partners, and patients. The completion of the divestiture of our Norwegian businesses fulfills our commitment to exit Europe. We remain focused on advancing a strategy to continue delivering sustainable growth and long-term value creation."
"As a result of our third quarter performance and operating momentum, we are raising and narrowing our guidance range for fiscal 2026 Adjusted Earnings per Diluted Share to $38.80 to $39.20. These strong outcomes reflect the power of our platforms and the dedication and commitment of Team McKesson, whose focus enables us to execute consistently and deliver high-quality results."
Fiscal 2026 Third Quarter Result Summary
| Third Quarter | Year-to-Date | |||||||||||||||||||||||||||||||||||||
| ($ in millions, except per share amounts) | FY26 | FY25 | Change | FY26 | FY25 | Change | ||||||||||||||||||||||||||||||||
| Revenues | $ | 106,158 | $ | 95,294 | 11 | % | $ | 307,135 | $ | 268,228 | 15 | % | ||||||||||||||||||||||||||
| Net income attributable to McKesson Corporation | 1,186 | 879 | 35 | 3,080 | 2,035 | 51 | ||||||||||||||||||||||||||||||||
Adjusted Earnings2 | 1,155 | 1,016 | 14 | 3,419 | 2,960 | 16 | ||||||||||||||||||||||||||||||||
| Earnings per diluted common share attributable to McKesson Corporation | 9.59 | 6.95 | 38 | 24.73 | 15.80 | 57 | ||||||||||||||||||||||||||||||||
Adjusted Earnings per Diluted Share2 | 9.34 | 8.03 | 16 | 27.46 | 22.97 | 20 | ||||||||||||||||||||||||||||||||
1 See below under "Fiscal 2026 Outlook" for full explanation 2 Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules | ||||||||||||||||||||||||||||||||||||||
Third quarter revenues were $106.2 billion, an increase of 11% from a year ago, driven by growth in the North American Pharmaceutical segment due to increased prescription volumes from retail national account customers and growth in the distribution of oncology and multispecialty products, including contributions from acquisitions in the Oncology & Multispecialty segment.
Third quarter earnings per diluted share was $9.59 compared to $6.95 a year ago, an increase of $2.64, which includes a pre-tax credit within the North American Pharmaceutical segment related to the Rite Aid bankruptcy.
Third quarter Adjusted Earnings per Diluted Share was $9.34 compared to $8.03 a year ago, an increase of 16%, driven by strong operational growth, including contributions from acquisitions in the Oncology & Multispecialty segment.
During the three months ended December 31, 2025, McKesson generated cash flow from operations of $1.2 billion, and invested $175 million in capital expenditures, resulting in Free Cash Flow of $1.1 billion. During the first nine months of the fiscal year, McKesson generated cash from operations of $2.7 billion, and invested $560 million in capital expenditures, resulting in Free Cash Flow of $2.2 billion.
For the first nine months of the fiscal year, McKesson returned $2.4 billion of cash to shareholders, which included $2.1 billion of common stock repurchases and $280 million of dividend payments.
Business Highlights
•On January 1, 2026, McKesson advanced its planned separation of the Medical-Surgical Solutions segment by implementing transition service agreements to support the business as it prepares to be an independent company.
•On January 30, 2026, McKesson closed the transaction to sell its retail and distribution businesses in Norway, representing the final phase to fully exit its European operations.
•In January, McKesson's Health Mart was honored with the prestigious H.A.B. Dunning Award from the American Pharmacists Association, recognizing outstanding contributions to advancing the profession and supporting community pharmacies nationwide.
North American Pharmaceutical Segment
•Revenues were $88.3 billion, an increase of 9%, driven by increased prescription transaction volumes, including higher volumes from retail national account customers and specialty products.
•Segment Operating Profit was $1.1 billion. Adjusted Segment Operating Profit was $872 million, an increase of 6%, driven by growth in the distribution of specialty products to health systems.
Oncology & Multispecialty Segment
•Revenues were $13.0 billion, an increase of 37%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.
•Segment Operating Profit was $304 million. Adjusted Segment Operating Profit was $366 million, an increase of 57%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.
Prescription Technology Solutions Segment
•Revenues were $1.5 billion, an increase of 9%, driven by increased prescription volumes in the third-party logistics and technology services businesses.
•Segment Operating Profit was $261 million. Adjusted Segment Operating Profit was $277 million, an increase of 18%, driven by higher demand for access solutions.
Medical-Surgical Solutions Segment
•Revenues were $3.0 billion, an increase of 1%, driven by higher volumes of specialty pharmaceuticals.
•Segment Operating Profit was $265 million. Adjusted Segment Operating Profit was $265 million, a decrease of 10%, driven by lower volumes across physician office settings and lower incidence of illness for the season.
Fiscal 2026 Outlook
McKesson does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.
McKesson is raising and narrowing its fiscal 2026 Adjusted Earnings per Diluted Share guidance to $38.80 to $39.20 from the previous range of $38.35 to $38.85.
Fiscal 2026 Adjusted Earnings per Diluted Share guidance includes $0.09 related to year-to-date gains associated with McKesson Ventures' equity investments.
Additional modeling considerations will be provided in the earnings call presentation.
Conference Call Details
McKesson has scheduled a conference call for today, Wednesday, February 4, 2026, at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at investor.mckesson.com.
Upcoming Investor Events
McKesson management will be participating in the following investor events:
•Leerink Partners Global Healthcare Conference, March 8-11, 2026
•Barclays Global Healthcare Conference, March 10-12, 2026
The audio webcasts, and a complete listing of upcoming events for the investment community, including details and updates, will be available on McKesson's Investor Relations website.
Non-GAAP Financial Measures
GAAP refers to the U.S. generally accepted accounting principles. This press release includes GAAP financial measures as well as Non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Other Income, Adjusted Interest Expense, Adjusted Income Tax Expense, Adjusted Earnings, Adjusted Earnings per Diluted Share, Adjusted Segment Operating Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses, Adjusted Operating Profit, and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the “Supplemental Non-GAAP Financial Information” section of the accompanying financial statement tables for the definitions and usefulness of the company’s Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.
Cautionary Statements
This earnings release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology. Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company, other anticipated or completed transactions, including the anticipated closings thereof, or synergies expected therefrom, litigation outcomes, financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, and intentions may also include forward-looking statements. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by law, we undertake no obligation to update or revise our forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.
These risk factors include, but are not limited to: we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws and policies; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we experience significant problems with information systems or networks; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted; we may not receive anticipated benefits from acquisitions or other strategic transactions; we might be adversely impacted by delays or other difficulties with divestitures; we are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies; our contracts with government entities involve funding, payment and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to risks and limitations that could impede the growth of our data services business; we might be unable to successfully recruit and retain qualified employees; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes; we are adversely impacted as a result of our distribution of generic pharmaceuticals; we are adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; we might be adversely impacted by conditions and events outside of our control, such as widespread public health issues, natural disasters, and geopolitical factors; we may be adversely affected by global climate change or by regulatory or market responses to such change; and evolving expectations and regulatory requirements related to governance and sustainability matters, including those concerning human capital management, climate change, environmental responsibility, and social impact may have an adverse effect on our business, financial condition, and results of operations and damage our reputation.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.
We routinely use our website, investors.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.
Contacts:
Investors
Investors@McKesson.com
Media Relations
MediaRelations@McKesson.com
Schedule 1
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (GAAP)
(unaudited)
(in millions, except per share amounts)
| Three Months Ended December 31, | Nine Months Ended December 31, | ||||||||||||||||||||||||||||||||||
| 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||
| Revenues | $ | 106,158 | $ | 95,294 | 11 | % | $ | 307,135 | $ | 268,228 | 15 | % | |||||||||||||||||||||||
| Cost of sales | (102,473) | (92,010) | 11 | (296,629) | (258,544) | 15 | |||||||||||||||||||||||||||||
| Gross profit | 3,685 | 3,284 | 12 | 10,506 | 9,684 | 8 | |||||||||||||||||||||||||||||
| Selling, distribution, general, and administrative expenses | (2,030) | (2,028) | — | (6,300) | (6,532) | (4) | |||||||||||||||||||||||||||||
| Claims and litigation charges, net | — | — | — | 2 | (108) | (102) | |||||||||||||||||||||||||||||
| Restructuring, impairment, and related charges, net | (36) | (32) | 13 | (146) | (213) | (31) | |||||||||||||||||||||||||||||
| Total operating expenses | (2,066) | (2,060) | — | (6,444) | (6,853) | (6) | |||||||||||||||||||||||||||||
| Operating income | 1,619 | 1,224 | 32 | 4,062 | 2,831 | 43 | |||||||||||||||||||||||||||||
| Other income, net | 74 | 69 | 7 | 200 | 233 | (14) | |||||||||||||||||||||||||||||
| Interest expense | (63) | (67) | (6) | (186) | (220) | (15) | |||||||||||||||||||||||||||||
| Income before income taxes | 1,630 | 1,226 | 33 | 4,076 | 2,844 | 43 | |||||||||||||||||||||||||||||
| Income tax expense | (380) | (298) | 28 | (832) | (669) | 24 | |||||||||||||||||||||||||||||
| Net income | 1,250 | 928 | 35 | 3,244 | 2,175 | 49 | |||||||||||||||||||||||||||||
| Net income attributable to noncontrolling interests | (64) | (49) | 31 | (164) | (140) | 17 | |||||||||||||||||||||||||||||
| Net income attributable to McKesson Corporation | $ | 1,186 | $ | 879 | 35 | % | $ | 3,080 | $ | 2,035 | 51 | % | |||||||||||||||||||||||
Earnings per common share attributable to McKesson Corporation (a) | |||||||||||||||||||||||||||||||||||
| Diluted | $ | 9.59 | $ | 6.95 | 38 | % | $ | 24.73 | $ | 15.80 | 57 | % | |||||||||||||||||||||||
| Basic | $ | 9.63 | $ | 6.98 | 38 | % | $ | 24.83 | $ | 15.88 | 56 | % | |||||||||||||||||||||||
| Dividends declared per common share | $ | 0.82 | $ | 0.71 | 15 | % | $ | 2.35 | $ | 2.04 | 15 | % | |||||||||||||||||||||||
| Weighted-average common shares outstanding | |||||||||||||||||||||||||||||||||||
| Diluted | 123.7 | 126.6 | (2) | % | 124.5 | 128.8 | (3) | % | |||||||||||||||||||||||||||
| Basic | 123.2 | 126.0 | (2) | 124.0 | 128.2 | (3) | % | ||||||||||||||||||||||||||||
(a)Certain computations may reflect rounding adjustments.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to our applicable filings with the SEC for additional disclosures including our Quarterly Reports on Form 10-Q for fiscal 2026 and 2025 as well as our
Annual Report on Form 10-K for fiscal 2025.
Schedule 2
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions, except per share amounts)
| Three Months Ended December 31, | Nine Months Ended December 31, | ||||||||||||||||||||||||||||||||||
| 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||
| Net income (GAAP) | $ | 1,250 | $ | 928 | 35 | % | $ | 3,244 | $ | 2,175 | 49 | % | |||||||||||||||||||||||
| Net income attributable to noncontrolling interests (GAAP) | (64) | (49) | 31 | (164) | (140) | 17 | |||||||||||||||||||||||||||||
| Net income attributable to McKesson Corporation (GAAP) | 1,186 | 879 | 35 | 3,080 | 2,035 | 51 | |||||||||||||||||||||||||||||
| Pre-tax adjustments: | |||||||||||||||||||||||||||||||||||
| Amortization of acquisition-related intangibles | 73 | 53 | 38 | 203 | 176 | 15 | |||||||||||||||||||||||||||||
Transaction-related expenses and adjustments (1) | 39 | 32 | 22 | 159 | 712 | (78) | |||||||||||||||||||||||||||||
| LIFO inventory-related adjustments | (10) | 89 | (111) | (28) | 85 | (133) | |||||||||||||||||||||||||||||
| Gains from antitrust legal settlements | (15) | (31) | (52) | (23) | (184) | (88) | |||||||||||||||||||||||||||||
Restructuring, impairment, and related charges, net (2) | 36 | 32 | 13 | 146 | 276 | (47) | |||||||||||||||||||||||||||||
Claims and litigation charges, net (3) | — | — | — | (2) | 108 | (102) | |||||||||||||||||||||||||||||
Other adjustments, net (4) (5) | (160) | — | — | 6 | (162) | 104 | |||||||||||||||||||||||||||||
| Income tax effect on pre-tax adjustments | 14 | (37) | 138 | (102) | (82) | 24 | |||||||||||||||||||||||||||||
| Net income attributable to noncontrolling interests effect on pre-tax adjustments | (8) | (1) | 700 | (20) | (4) | 400 | |||||||||||||||||||||||||||||
| Adjusted Earnings (Non-GAAP) | $ | 1,155 | $ | 1,016 | 14 | % | $ | 3,419 | $ | 2,960 | 16 | % | |||||||||||||||||||||||
Earnings per diluted common share attributable to McKesson Corporation (GAAP) (a) | $ | 9.59 | $ | 6.95 | 38 | % | $ | 24.73 | $ | 15.80 | 57 | % | |||||||||||||||||||||||
| After-tax adjustments: | |||||||||||||||||||||||||||||||||||
| Amortization of acquisition-related intangibles | 0.38 | 0.31 | 23 | 1.08 | 1.00 | 8 | |||||||||||||||||||||||||||||
| Transaction-related expenses and adjustments | 0.26 | 0.24 | 8 | 1.06 | 5.47 | (81) | |||||||||||||||||||||||||||||
| LIFO inventory-related adjustments | (0.06) | 0.52 | (112) | (0.17) | 0.49 | (135) | |||||||||||||||||||||||||||||
| Gains from antitrust legal settlements | (0.09) | (0.18) | (50) | (0.14) | (1.06) | (87) | |||||||||||||||||||||||||||||
| Restructuring, impairment, and related charges, net | 0.21 | 0.19 | 11 | 0.87 | 1.58 | (45) | |||||||||||||||||||||||||||||
| Claims and litigation charges, net | — | — | — | (0.02) | 0.62 | (103) | |||||||||||||||||||||||||||||
| Other adjustments, net | (0.95) | — | — | 0.05 | (0.93) | 105 | |||||||||||||||||||||||||||||
Adjusted Earnings per Diluted Share (Non-GAAP) (a) | $ | 9.34 | $ | 8.03 | 16 | % | $ | 27.46 | $ | 22.97 | 20 | % | |||||||||||||||||||||||
| Diluted weighted-average common shares outstanding | 123.7 | 126.6 | (2) | % | 124.5 | 128.8 | (3) | % | |||||||||||||||||||||||||||
(a)Certain computations may reflect rounding adjustments.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Earnings (Non-GAAP) and Adjusted Earnings per Diluted Share (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Schedule 2 (continued)
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
| Three Months Ended December 31, | Nine Months Ended December 31, | ||||||||||||||||||||||||||||||||||
| 2025 | 2024 | Change | 2025 | 2024 | Change | ||||||||||||||||||||||||||||||
| Gross profit (GAAP) | $ | 3,685 | $ | 3,284 | 12 | % | $ | 10,506 | $ | 9,684 | 8 | % | |||||||||||||||||||||||
| Pre-tax adjustments: | |||||||||||||||||||||||||||||||||||
| LIFO inventory-related adjustments | (10) | 89 | (111) | (28) | 85 | (133) | |||||||||||||||||||||||||||||
| Gains from antitrust legal settlements | (15) | (31) | (52) | (23) | (184) | (88) | |||||||||||||||||||||||||||||
| Restructuring, impairment, and related charges, net | — | — | — | — | 63 | (100) | |||||||||||||||||||||||||||||
| Other adjustments, net | 2 | — | — | 5 | — | — | |||||||||||||||||||||||||||||
| Adjusted Gross Profit (Non-GAAP) | $ | 3,662 | $ | 3,342 | 10 | % | $ | 10,460 | $ | 9,648 | 8 | % | |||||||||||||||||||||||
| Total operating expenses (GAAP) | $ | (2,066) | $ | (2,060) | — | % | $ | (6,444) | $ | (6,853) | (6) | % | |||||||||||||||||||||||
| Pre-tax adjustments: | |||||||||||||||||||||||||||||||||||
| Amortization of acquisition-related intangibles | 73 | 53 | 38 | 203 | 176 | 15 | |||||||||||||||||||||||||||||
Transaction-related expenses and adjustments (1) | 35 | 27 | 30 | 144 | 697 | (79) | |||||||||||||||||||||||||||||
Restructuring, impairment, and related charges, net (2) | 36 | 32 | 13 | 146 | 213 | (31) | |||||||||||||||||||||||||||||
Claims and litigation charges, net (3) | — | — | — | (2) | 108 | (102) | |||||||||||||||||||||||||||||
Other adjustments, net (4) | (162) | — | — | 1 | (205) | 100 | |||||||||||||||||||||||||||||
| Adjusted Operating Expenses (Non-GAAP) | $ | (2,084) | $ | (1,948) | 7 | % | $ | (5,952) | $ | (5,864) | 2 | % | |||||||||||||||||||||||
| Other income, net (GAAP) | $ | 74 | $ | 69 | 7 | % | $ | 200 | $ | 233 | (14) | % | |||||||||||||||||||||||
| Pre-tax adjustments: | |||||||||||||||||||||||||||||||||||
| Transaction-related expenses and adjustments | — | — | — | — | (1) | (100) | |||||||||||||||||||||||||||||
Other adjustments, net (5) | — | — | — | — | 43 | (100) | |||||||||||||||||||||||||||||
| Adjusted Other Income (Non-GAAP) | $ | 74 | $ | 69 | 7 | % | $ | 200 | $ | 275 | (27) | % | |||||||||||||||||||||||
| Interest expense (GAAP) | $ | (63) | $ | (67) | (6) | % | $ | (186) | $ | (220) | (15) | % | |||||||||||||||||||||||
| Pre-tax adjustments: | |||||||||||||||||||||||||||||||||||
| Transaction-related expenses and adjustments | 4 | 5 | (20) | 15 | 16 | (6) | |||||||||||||||||||||||||||||
| Adjusted Interest Expense (Non-GAAP) | $ | (59) | $ | (62) | (5) | % | $ | (171) | $ | (204) | (16) | % | |||||||||||||||||||||||
| Income tax expense (GAAP) | $ | (380) | $ | (298) | 28 | % | $ | (832) | $ | (669) | 24 | % | |||||||||||||||||||||||
| Tax adjustments: | |||||||||||||||||||||||||||||||||||
| Amortization of acquisition-related intangibles | (18) | (13) | 38 | (48) | (43) | 12 | |||||||||||||||||||||||||||||
Transaction-related expenses and adjustments (1) | (7) | (1) | 600 | (28) | (8) | 250 | |||||||||||||||||||||||||||||
| LIFO inventory-related adjustments | 2 | (23) | 109 | 7 | (22) | 132 | |||||||||||||||||||||||||||||
| Gains from antitrust legal settlements | 4 | 8 | (50) | 6 | 48 | (88) | |||||||||||||||||||||||||||||
Restructuring, impairment, and related charges, net (2) | (9) | (8) | 13 | (38) | (72) | (47) | |||||||||||||||||||||||||||||
Claims and litigation charges, net (3) | — | — | — | — | (28) | (100) | |||||||||||||||||||||||||||||
Other adjustments, net (4) (5) | 42 | — | — | (1) | 43 | (102) | |||||||||||||||||||||||||||||
| Adjusted Income Tax Expense (Non-GAAP) | $ | (366) | $ | (335) | 9 | % | $ | (934) | $ | (751) | 24 | % | |||||||||||||||||||||||
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Gross Profit (Non-GAAP), Adjusted Operating Expenses (Non-GAAP), Adjusted Other Income (Non-GAAP), Adjusted Interest Expense (Non-GAAP), and Adjusted Income Tax Expense (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Schedule 3
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
| Three Months Ended December 31, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | Change | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| As reported (GAAP) | Adjustments | As adjusted (Non-GAAP) | As reported (GAAP) | Adjustments | As adjusted (Non-GAAP) | As reported (GAAP) | As adjusted (Non-GAAP) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| REVENUES | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| North American Pharmaceutical | $ | 88,322 | $ | — | $ | 88,322 | $ | 81,198 | $ | — | $ | 81,198 | 9 | % | 9 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oncology & Multispecialty | 13,010 | — | 13,010 | 9,493 | — | 9,493 | 37 | 37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prescription Technology Solutions | 1,500 | — | 1,500 | 1,371 | — | 1,371 | 9 | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical-Surgical Solutions | 2,991 | — | 2,991 | 2,949 | — | 2,949 | 1 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | 335 | — | 335 | 283 | — | 283 | 18 | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues | $ | 106,158 | $ | — | $ | 106,158 | $ | 95,294 | $ | — | $ | 95,294 | 11 | % | 11 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| OPERATING PROFIT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
North American Pharmaceutical (1) (2) | $ | 1,055 | $ | (183) | $ | 872 | $ | 744 | $ | 78 | $ | 822 | 42 | % | 6 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oncology & Multispecialty | 304 | 62 | 366 | 202 | 31 | 233 | 50 | 57 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prescription Technology Solutions | 261 | 16 | 277 | 219 | 16 | 235 | 19 | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical-Surgical Solutions (2) | 265 | — | 265 | 269 | 25 | 294 | (1) | (10) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | 31 | (3) | 28 | 14 | (3) | 11 | 121 | 155 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Subtotal | 1,916 | (108) | 1,808 | 1,448 | 147 | 1,595 | 32 | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corporate expenses, net (1) (2) | (223) | 67 | (156) | (155) | 23 | (132) | 44 | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income before interest expense and income taxes | $ | 1,693 | $ | (41) | $ | 1,652 | $ | 1,293 | $ | 170 | $ | 1,463 | 31 | % | 13 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| OPERATING PROFIT AS A % OF REVENUES | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| North American Pharmaceutical | 1.19 | % | 0.99 | % | 0.92 | % | 1.01 | % | 27 | bp | (2) | bp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oncology & Multispecialty | 2.34 | 2.81 | 2.13 | 2.45 | 21 | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prescription Technology Solutions | 17.40 | 18.47 | 15.97 | 17.14 | 143 | 133 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical-Surgical Solutions | 8.86 | 8.86 | 9.12 | 9.97 | (26) | (111) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | 9.25 | 8.36 | 4.95 | 3.89 | 430 | 447 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Segment Operating Profit (Non-GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Schedule 3 (continued)
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
| Nine Months Ended December 31, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | Change | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| As reported (GAAP) | Adjustments | As adjusted (Non-GAAP) | As reported (GAAP) | Adjustments | As adjusted (Non-GAAP) | As reported (GAAP) | As adjusted (Non-GAAP) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| REVENUES | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| North American Pharmaceutical | $ | 257,532 | $ | — | $ | 257,532 | $ | 227,564 | $ | — | $ | 227,564 | 13 | % | 13 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oncology & Multispecialty | 35,712 | — | 35,712 | 27,431 | — | 27,431 | 30 | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prescription Technology Solutions | 4,310 | — | 4,310 | 3,877 | — | 3,877 | 11 | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical-Surgical Solutions | 8,639 | — | 8,639 | 8,527 | — | 8,527 | 1 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | 942 | — | 942 | 829 | — | 829 | 14 | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues | $ | 307,135 | $ | — | $ | 307,135 | $ | 268,228 | $ | — | $ | 268,228 | 15 | % | 15 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| OPERATING PROFIT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
North American Pharmaceutical (1) (2) (3) (4) | $ | 2,501 | $ | (29) | $ | 2,472 | $ | 1,793 | $ | 467 | $ | 2,260 | 39 | % | 9 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oncology & Multispecialty (5) | 848 | 202 | 1,050 | 550 | 134 | 684 | 54 | 54 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prescription Technology Solutions | 758 | 49 | 807 | 627 | 49 | 676 | 21 | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical-Surgical Solutions (2) | 706 | 52 | 758 | 552 | 185 | 737 | 28 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | 72 | (6) | 66 | 44 | (5) | 39 | 64 | 69 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Subtotal | 4,885 | 268 | 5,153 | 3,566 | 830 | 4,396 | 37 | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corporate expenses, net (1) (2) (3) (6) | (623) | 178 | (445) | (502) | 165 | (337) | 24 | 32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income before interest expense and income taxes | $ | 4,262 | $ | 446 | $ | 4,708 | $ | 3,064 | $ | 995 | $ | 4,059 | 39 | % | 16 | % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| OPERATING PROFIT AS A % OF REVENUES | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| North American Pharmaceutical | 0.97 | % | 0.96 | % | 0.79 | % | 0.99 | % | 18 | bp | (3) | bp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oncology & Multispecialty | 2.37 | 2.94 | 2.01 | 2.49 | 36 | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Prescription Technology Solutions | 17.59 | 18.72 | 16.17 | 17.44 | 142 | 128 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical-Surgical Solutions | 8.17 | 8.77 | 6.47 | 8.64 | 170 | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | 7.64 | 7.01 | 5.31 | 4.70 | 233 | 231 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Segment Operating Profit (Non-GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Schedule 4
McKESSON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions, except per share amounts)
| December 31, 2025 | March 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 2,959 | $ | 5,691 | |||||||
| Receivables, net | 28,213 | 25,643 | |||||||||
| Inventories, net | 27,067 | 23,001 | |||||||||
| Prepaid expenses and other | 1,458 | 1,063 | |||||||||
| Total current assets | 59,697 | 55,398 | |||||||||
| Property, plant, and equipment, net | 2,634 | 2,502 | |||||||||
| Operating lease right-of-use assets | 2,056 | 1,782 | |||||||||
| Goodwill | 11,324 | 10,022 | |||||||||
| Intangible assets, net | 4,179 | 1,464 | |||||||||
| Other non-current assets | 4,300 | 3,972 | |||||||||
| Total assets | $ | 84,190 | $ | 75,140 | |||||||
| LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS, AND DEFICIT | |||||||||||
| Current liabilities | |||||||||||
| Drafts and accounts payable | $ | 60,683 | $ | 55,330 | |||||||
| Current portion of long-term debt | 1,132 | 1,191 | |||||||||
| Current portion of operating lease liabilities | 286 | 258 | |||||||||
| Other accrued liabilities | 6,030 | 4,825 | |||||||||
| Total current liabilities | 68,131 | 61,604 | |||||||||
| Long-term debt | 5,425 | 4,463 | |||||||||
| Long-term deferred tax liabilities | 1,108 | 1,029 | |||||||||
| Long-term operating lease liabilities | 1,781 | 1,478 | |||||||||
| Long-term litigation liabilities | 5,103 | 5,601 | |||||||||
| Other non-current liabilities | 2,741 | 2,659 | |||||||||
| Redeemable noncontrolling interests | 802 | — | |||||||||
| McKesson Corporation stockholders’ deficit | |||||||||||
| Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding | — | — | |||||||||
Common stock, $0.01 par value, 800 shares authorized, 280 and 279 shares issued at December 31, 2025 and March 31, 2025, respectively | 3 | 3 | |||||||||
| Additional paid-in capital | 8,546 | 8,373 | |||||||||
| Retained earnings | 20,710 | 17,921 | |||||||||
| Accumulated other comprehensive loss | (903) | (932) | |||||||||
Treasury shares, at cost, 157 and 154 shares at December 31, 2025 and March 31, 2025, respectively | (29,654) | (27,439) | |||||||||
| Total McKesson Corporation stockholders’ deficit | (1,298) | (2,074) | |||||||||
| Noncontrolling interests | 397 | 380 | |||||||||
| Total deficit | (901) | (1,694) | |||||||||
| Total liabilities, redeemable noncontrolling interests, and deficit | $ | 84,190 | $ | 75,140 | |||||||
Schedule 5
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in millions)
| Nine Months Ended December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| OPERATING ACTIVITIES | |||||||||||
| Net income | $ | 3,244 | $ | 2,175 | |||||||
| Adjustments to reconcile to net cash used in operating activities: | |||||||||||
| Depreciation | 189 | 182 | |||||||||
| Amortization | 344 | 303 | |||||||||
| Asset impairment charges | 10 | 83 | |||||||||
| Deferred taxes | 8 | 150 | |||||||||
| Charges (credits) associated with last-in, first-out inventory method | (28) | 85 | |||||||||
| Non-cash operating lease expense | 184 | 179 | |||||||||
| Loss (gain) from sales of businesses and investments | (85) | 571 | |||||||||
| Provision for bad debts | 81 | (144) | |||||||||
| Other non-cash items | 209 | 211 | |||||||||
| Changes in assets and liabilities: | |||||||||||
| Receivables | (2,130) | (4,064) | |||||||||
| Inventories | (4,098) | (3,134) | |||||||||
| Drafts and accounts payable | 4,891 | 2,677 | |||||||||
| Operating lease liabilities | (202) | (305) | |||||||||
| Taxes | 184 | (288) | |||||||||
| Litigation liabilities | (669) | (386) | |||||||||
| Other | 602 | 42 | |||||||||
| Net cash provided by (used in) operating activities | 2,734 | (1,663) | |||||||||
| INVESTING ACTIVITIES | |||||||||||
| Payments for property, plant, and equipment | (325) | (368) | |||||||||
| Capitalized software expenditures | (235) | (213) | |||||||||
| Acquisitions, net of cash, cash equivalents, and restricted cash acquired | (3,412) | (3) | |||||||||
| Proceeds from sales of businesses and investments, net | 137 | 83 | |||||||||
| Other | (22) | (8) | |||||||||
| Net cash used in investing activities | (3,857) | (509) | |||||||||
| FINANCING ACTIVITIES | |||||||||||
| Proceeds from short-term borrowings | 2,275 | 11,395 | |||||||||
| Repayments of short-term borrowings | (2,275) | (8,970) | |||||||||
| Proceeds from issuances of long-term debt | 1,990 | 498 | |||||||||
| Repayments of long-term debt | (1,199) | (510) | |||||||||
| Common stock transactions: | |||||||||||
| Issuances | 65 | 73 | |||||||||
| Share repurchases | (2,079) | (2,846) | |||||||||
| Dividends paid | (280) | (254) | |||||||||
| Other | (308) | (496) | |||||||||
| Net cash used in financing activities | (1,811) | (1,110) | |||||||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 31 | (21) | |||||||||
| Net decrease in cash, cash equivalents, and restricted cash | (2,903) | (3,303) | |||||||||
| Cash, cash equivalents, and restricted cash at beginning of period | 5,956 | 4,585 | |||||||||
| Cash, cash equivalents, and restricted cash at end of period | 3,053 | 1,282 | |||||||||
| Less: Restricted cash at end of period included in Prepaid expenses and other | (94) | (151) | |||||||||
| Cash and cash equivalents at end of period | $ | 2,959 | $ | 1,131 | |||||||
Schedule 6
McKESSON CORPORATION
RECONCILIATION OF GAAP CASH FLOW TO FREE CASH FLOW (NON-GAAP)
(unaudited)
(in millions)
Three Months Ended December 31,(1) | Nine Months Ended December 31, | ||||||||||||||||||||||
| 2025 | 2025 | 2024 | Change | ||||||||||||||||||||
| GAAP CASH FLOW CATEGORIES | |||||||||||||||||||||||
| Net cash provided by (used in) operating activities | $ | 1,232 | $ | 2,734 | $ | (1,663) | 264 | % | |||||||||||||||
| Net cash used in investing activities | (269) | (3,857) | (509) | 658 | |||||||||||||||||||
| Net cash used in financing activities | (2,026) | (1,811) | (1,110) | 63 | |||||||||||||||||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 7 | 31 | (21) | 248 | |||||||||||||||||||
| Net decrease in cash, cash equivalents, and restricted cash | $ | (1,056) | $ | (2,903) | $ | (3,303) | (12) | % | |||||||||||||||
| FREE CASH FLOW (NON-GAAP) | |||||||||||||||||||||||
| Net cash provided by (used in) operating activities | $ | 1,232 | $ | 2,734 | $ | (1,663) | 264 | % | |||||||||||||||
| Payments for property, plant, and equipment | (108) | (325) | (368) | (12) | |||||||||||||||||||
| Capitalized software expenditures | (67) | (235) | (213) | 10 | |||||||||||||||||||
| Free Cash Flow (Non-GAAP) | $ | 1,057 | $ | 2,174 | $ | (2,244) | 197 | % | |||||||||||||||
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
For more information relating to the Free Cash Flow (Non-GAAP) definition, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
1) Amounts for the three months ended December 31, 2025 were derived using fiscal 2026 year-to-date Net cash provided by operating activities, Net cash used in investing activities, Net cash provided by (used in) financing activities, Effect of exchange rate changes on cash and cash equivalents, and restricted cash, Payments for property, plant and equipment, and Capitalized software expenditures, less the comparative amounts for the six months ended September 30, 2025 of fiscal 2026.
1 of 1
McKESSON CORPORATION
FINANCIAL STATEMENT NOTES
1.Transaction-related expenses and adjustments for the three and nine months ended December 31, 2024 includes a net loss of $23 million (pre-tax and after-tax) and $666 million (pre-tax and after-tax), respectively, to remeasure assets and liabilities held for sale to fair value less costs to sell related to an agreement to sell certain of our Canadian businesses. Net charges (pre-tax and after-tax) of $11 million included within North American Pharmaceutical, and $12 million included within Corporate expenses, net, and $604 million included within North American Pharmaceutical, and $62 million included within Corporate expenses, net, respectively, for the three and nine months ended December 31, 2024. These net charges are primarily to remeasure assets and liabilities held for sale to fair value less costs to sell, including the effect of accumulated other comprehensive income balances associated with the disposal group, and are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
2.Restructuring, impairment, and related charges, net for the three and nine months ended December 31, 2025 includes pre-tax charges of $36 million ($27 million after-tax) and $146 million ($108 million after tax), respectively, primarily within Medical-Surgical Solutions and Corporate Expenses, net. The three and nine months ended December 31, 2024 includes pre-tax charges of $32 million ($24 million after-tax) and $276 million ($204 million after-tax), respectively, primarily within Medical-Surgical Solutions, North American Pharmaceutical, and Corporate expenses, net. These charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
3.Claims and litigation charges, net for the nine months ended December 31, 2024 includes pre-tax charges of $114 million ($86 million after-tax) related to our estimated liability for opioid-related claims of a nationwide group of certain third-party payors. We recorded charges of $57 million ($43 million after-tax) within Corporate expenses, net and $57 million ($43 million after-tax) within North American Pharmaceutical. These charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
4.Other adjustments, net for the three and nine months ended December 31, 2025 includes a pre-tax credit of $160 million ($118 million after-tax) and a pre-tax charge of $29 million ($22 million after tax), respectively, and for the nine months ended December 31, 2024 includes a pre-tax credit of $203 million ($150 million after-tax), within North American Pharmaceutical related to the bankruptcy of our customer, Rite Aid Corporation (including certain of its subsidiaries, "Rite Aid"). Management believes this charge/credit is not reflective of allowances recorded in the normal course of business operations and is related to Rite Aid's continued bankruptcy proceedings, and is therefore excluded from the determination of our adjusted results (Non-GAAP). This charge/credit is included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
5.Other adjustments, net for the nine months ended December 31, 2024 includes a pre-tax charge of $43 million ($31 million after-tax) within Oncology & Multispecialty related to a loss from one of the Company's investments in equity securities. This charge is included under "other income, net" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
6.During the nine months ended December 31, 2024, the Company recognized a pre-tax net gain of $100 million ($74 million after-tax) within Corporate expenses, net related to a recapitalization event of one of our investments in equity securities, which resulted in an increase to the carrying value of this investment. This gain was recorded in “Other income, net” in the Condensed Consolidated Statements of Operations (GAAP) provided in Schedule 1 of the accompanying financial statement tables.
1 of 3
McKESSON CORPORATION
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION
In an effort to provide investors with additional information regarding the Company's financial results as determined by generally accepted accounting principles ("GAAP"), McKesson Corporation (the "Company" or "we") also presents the following Non-GAAP measures in this press release.
•Adjusted Gross Profit (Non-GAAP): We define Adjusted Gross Profit as GAAP gross profit, excluding transaction-related expenses and adjustments, last-in, first-out (“LIFO”) inventory-related adjustments, gains from antitrust legal settlements, and other adjustments.
•Adjusted Operating Expenses (Non-GAAP): We define Adjusted Operating Expenses as GAAP total operating expenses, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
•Adjusted Other Income (Non-GAAP): We define Adjusted Other Income as GAAP other income (expense), net, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, and other adjustments.
•Adjusted Interest Expense (Non-GAAP): We define Adjusted Interest Expense as GAAP interest expense, excluding transaction-related expenses and adjustments related to net interest expense incurred from cross-currency swaps used to hedge the changes in the fair value of the Company's foreign currency-denominated notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The foreign currency-denominated notes were previously designated as non-derivative net investment hedges of portions of the Company's net investments in its now-divested European businesses against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar.
•Adjusted Income Tax Expense (Non-GAAP): We define Adjusted Income Tax Expense as GAAP income tax benefit (expense), excluding the income tax effects of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments. Income tax effects are calculated in accordance with Accounting Standards Codification ("ASC") 740, “Income Taxes,” which is the same accounting principle used by the Company when presenting its GAAP financial results.
•Adjusted Earnings (Non-GAAP): We define Adjusted Earnings as GAAP income attributable to McKesson, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments, as well as the related income tax effects for each of these items, as applicable.
•Adjusted Earnings per Diluted Share (Non-GAAP): We define Adjusted Earnings per Diluted Share as GAAP earnings per diluted common share attributable to McKesson, excluding per share impacts of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments, as well as the related income tax effects for each of these items, as applicable, divided by diluted weighted-average shares outstanding.
•Adjusted Segment Operating Profit (Non-GAAP) and Adjusted Segment Operating Profit Margin (Non-GAAP): We define Adjusted Segment Operating Profit as GAAP segment operating profit, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, and other adjustments. We define Adjusted Segment Operating Profit Margin as Adjusted Segment Operating Profit (Non-GAAP) divided by GAAP segment revenues.
•Adjusted Corporate Expenses (Non-GAAP): We define Adjusted Corporate Expenses as GAAP corporate expenses, net, excluding transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
2 of 3
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
•Adjusted Operating Profit (Non-GAAP): We define Adjusted Operating Profit as GAAP income before interest expense and income taxes, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
The following provides further details regarding the adjustments made to our GAAP financial results to arrive at our Non-GAAP measures as defined above:
Amortization of acquisition-related intangibles - Amortization charges for intangible assets directly related to business combinations and the formation of joint ventures.
Transaction-related expenses and adjustments - Transaction, integration, and other expenses that are directly related to business combinations, the formation of joint ventures, divestitures, and other transaction-related costs including initial public offering costs. Examples include transaction closing costs, professional service fees, legal fees, severance charges, retention payments and employee relocation expenses, facility or other exit-related expenses, certain fair value adjustments including deferred revenues, contingent consideration and inventory, recoveries of acquisition-related expenses or post-closing expenses, net interest expense impact of hedging foreign currency-denominated notes, bridge loan fees and gains or losses on business combinations, and divestitures of businesses that do not qualify as discontinued operations.
LIFO inventory-related adjustments - LIFO inventory-related non-cash charges or credit adjustments.
Gains from antitrust legal settlements - Net cash proceeds representing the Company’s share of antitrust legal settlements.
Restructuring, impairment, and related charges - Restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted as well as long-lived asset impairments. Such charges may include employee severance, retention bonuses, facility closure or consolidation costs, lease or contract termination costs, asset impairments, accelerated depreciation and amortization, and other related expenses. The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, integration of acquired businesses, and/or company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of our underlying business, which include normal levels of reinvestment in the business. Any credit adjustments due to subsequent changes in estimates are also excluded from adjusted results.
Claims and litigation charges - Adjustments to certain of the Company’s reserves, including those related to estimated probable settlements for its controlled substance monitoring and reporting, and opioid-related claims, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred. This also may include charges or credits for general non-operational claims not directly related to our ongoing business.
Other adjustments - The Company evaluates the nature and significance of transactions qualitatively and quantitatively on an individual basis and may include them in the determination of our adjusted results from time to time. While not all-inclusive, other adjustments may include: other asset impairments; gains or losses from debt extinguishment; and other similar substantive and/or infrequent items as deemed appropriate.
The Company evaluates the aforementioned Non-GAAP measures on a periodic basis and updates the definitions from time to time. The evaluation considers both the quantitative and qualitative aspects of the Company’s presentation of Non-GAAP adjusted results. A reconciliation of McKesson’s GAAP financial results to Non-GAAP financial results is provided in Schedules 2 and 3 of the financial statement tables included with this press release.
•Free Cash Flow (Non-GAAP): We define free cash flow as net cash provided by (used in) operating activities less payments for property, plant, and equipment and capitalized software expenditures, as disclosed in our condensed consolidated statements of cash flows. A reconciliation of McKesson’s GAAP financial results to Free Cash Flow (Non-GAAP) is provided in Schedule 6 of the financial statement tables included with this press release.
3 of 3
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
The Company believes the presentation of Non-GAAP measures provides useful supplemental information to investors with regard to its operating performance, as well as assists with the comparison of its past financial performance to the Company’s future financial results. Moreover, the Company believes that the presentation of Non-GAAP measures assists investors’ ability to compare its financial results to those of other companies in the same industry. However, the Company's Non-GAAP measures used in the press tables may be defined and calculated differently by other companies in the same industry.
The Company internally uses both GAAP and Non-GAAP financial measures in connection with its own financial planning and reporting processes. Management utilizes Non-GAAP financial measures when allocating resources, deploying capital, as well as assessing business performance, and determining employee incentive compensation. The Company conducts its businesses internationally in local currencies, including Canadian dollars, Euro, and British pound sterling. As a result, the comparability of our results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. We believe free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, re-investment opportunities, strategic acquisitions, share repurchases, dividend payments, or other strategic uses of cash. Nonetheless, Non-GAAP adjusted results and related Non-GAAP measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.